Good morning, and welcome to the MindMed full year 2021 financial results and corporate update conference call. Currently, all participants are on a listen-only mode. This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co, and a recording will be available after the call. For opening remarks, I will turn the call over to Robert Barrow, CEO of MindMed. Thank you. Please go ahead. Thank you, and good morning, everyone. Welcome to our full year 2021 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of MindMed's website, and our annual report on Form 10-K for the year ended December 31, 2021 will be filed today with the Securities and Exchange Commission. Joining me today is Dr. Dan Karlin, our Chief Medical Officer, and Dr. Miri Halperin Wernli, our Executive President. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, financial projections, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including the most recent annual report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which are made as of today, March 28, 2022. MindMed disclaims any obligation to update such statements, even if management views change. Before we dive into our program and corporate update, I feel it is important to acknowledge the backdrop against which we have embarked on our mission to revolutionize the treatment of brain health disorders. The social isolation of the COVID-19 pandemic, the realities of climate change, the tragedies of war and refugee crises have contributed to soaring rates of anxiety, depression, substance abuse, and other brain disorders. The good news is that there has been a significant resurgence in research of novel therapies to treat these conditions, and MindMed is leading the way in this effort. We have big ambitions to revolutionize the treatment of brain health disorders by delivering on the therapeutic potential of psychedelics and other novel drug classes. We are applying our pharmaceutical expertise to develop these innovative therapies with the aim of generating rapid and sustained improvements in patient outcomes, with applicability to anxiety, addiction, and even autism. This matters today more than ever. The incredible team we've assembled at MindMed has unmatched expertise, and we are utilizing decades of academic research to accelerate our three lead drug candidates, MM-120, MM-110, and MM-402, along with other novel therapies. We are extremely pleased with the progress and transformational growth that propelled our business forward over the past year. We made significant strides to advance all of our product candidates, and as I speak to you today, I believe MindMed has never been in a better position to become the leader in developing novel therapies to treat brain health disorders and to improve patient outcomes in areas of unmet medical need. I will now turn the call over to our Chief Medical Officer, Dr. Dan Karlin, to provide additional updates on each of our development programs. Dan? Thank you, Rob. Our drug pipeline at MindMed is comprised of a wide array of exciting product candidates that are either currently in or are nearing clinical trials. On this call, I will focus on the programs with the most near-term visibility and highlight upcoming milestones, starting with our lead drug candidate, MM-120. MM-120 is a proprietary pharmaceutically optimized form of LSD that we are developing for the treatment of generalized anxiety disorder, or GAD. GAD is an often debilitating mental health disorder that affects approximately 6% of U.S. adults in their lifetimes. Symptoms of GAD include excessive anxiety and worry that persists for over six months, which can lead to significant impairments in social, occupational, and other functioning. There has been very little innovation focused on the treatment of GAD over the past several decades. In January of this year, FDA cleared our investigational new drug application, or IND, for our phase IIb dose optimization trial of MM-120 for the treatment of GAD. This trial is expected to initiate in the second quarter of 2022, with top line results expected in late 2023. The trial plans to enroll a total of 200 participants who will receive a single administration of up to 200 micrograms of MM-120 or placebo. The primary objective of the study is to determine the reduction in anxiety symptoms for up to 12 weeks after a single administration of MM-120 across 5 treatment arms. I wanna thank our dedicated clinical and regulatory teams here at MindMed for all their hard work in rapidly addressing the clinical hold related to the participant monitoring aspects of the protocol. Overcoming this regulatory hurdle represents a significant milestone for MindMed and for the industry as a whole, as it marks the first large commercially sponsored study of LSD in more than 40 years. The results of this trial will guide the dose selection and development strategy for our pivotal phase III clinical trials, as well as deepen our scientific understanding of the clinical effects of MM-120 and its underlying mechanisms of action. With a clear regulatory path, we look forward to building on this momentum and advancing this trial as quickly and efficiently as possible to address the unmet needs of patients who suffer from GAD. In parallel, we are currently enrolling patients in our phase IIa proof of concept trial of MM-120 for the treatment of ADHD. We expect top-line data in late 2023. While ADHD is often associated with children and adolescents, adults living with the disease face numerous challenges, from debilitating struggles with time management and impulsivity to mood swings and disorganization. Between 2007 and 2016 alone, the rate of ADHD among adults increased by 123%. Of the estimated 10 million American adults with ADHD, it is estimated that only about 10% seek and receive treatment for their condition. Interestingly, there is anecdotal evidence suggesting psychedelics such as LSD have beneficial and lasting effects on mood and selective cognitive processes when administered repeatedly at low doses. Further, low doses of LSD have been shown to be safe, well tolerated, and have minimal effects on physiological parameters. This phase IIa POC trial is being conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands, and is designed to evaluate the therapeutic utility of repeated low doses of LSD in adult patients with ADHD. The trial plans to enroll a total of 52 participants who will receive a 20-microgram dose of MM-120 or placebo twice weekly for six weeks. The primary endpoints for this study are mean change from baseline in ADHD symptoms as assessed by the AISRS after six weeks of treatment. We look forward to driving this exploratory trial forward as part of our broader comprehensive LSD clinical development strategy. In addition to our ongoing phase II studies for MM-120 in GAD and ADHD, we are currently advancing our strategic plans for MM-120 in the treatment of select pain conditions and plan to initiate a clinical study of MM-120 in chronic pain in late 2022. Moving on to our work in substance use disorders. The ongoing and ever-growing opioid crisis claims over 75,000 lives each year and impacts the lives of countless others. While ibogaine has been used and studied as a treatment for opioid addiction, its efficacy, while promising, has been overshadowed by significant safety concerns. Our proprietary molecule, MM-110, also known as zolunicant and 18-MC, is an α3β4 nicotinic cholinergic receptor antagonist that has been tested extensively in preclinical models of withdrawal and substance use disorders. MM-110 was demonstrated to reduce signs of opioid withdrawal and reduce self-administration of opioids, stimulants, nicotine, and ethanol. Extensive preclinical characterization has also shown zolunicant to have a strong safety and tolerability profile. Importantly, zolunicant has the potential to overcome safety limitations of ibogaine and has not demonstrated pro-arrhythmic or neurotoxic activity. We recently completed a phase I study of MM-110 in late 2021, which assessed the safety, tolerability, pharmacokinetics, and cognitive effects of MM-110 in healthy volunteers. In this phase I single ascending dose and multiple ascending dose trial, subjects either received doses between 4 and 325 milligrams twice per day for one day, or doses between 2 and 90 milligrams twice per day for up to 7 days. We plan to release top-line data from the phase I study and to initiate our phase IIa clinical trial of MM-110 in opioid withdrawal in the second quarter of 2022. Turning to a few key updates on our third lead program, MM-402 or R-MDMA, which is a synthetic, an enantiomer of MDMA that exhibits prosocial and empathogenic activity in preclinical models. We are developing MM-402 for the treatment of the core symptoms of autism spectrum disorder or ASD, which is a developmental disorder characterized by atypical social communication and interactions, repetitive patterns of behavior, and restricted interests. Despite its significant and growing prevalence, there are no therapies approved to treat the core symptoms of ASD with currently used medications serving either to treat comorbid disorders or used for behavioral control. Our hope for MM-402 is to demonstrate efficacy at enhancing social engagement and interaction rather than having sedating or blunting effects on individuals with ASD. Preclinical studies of R-MDMA demonstrate its acute prosocial effects while its diminished dopaminergic activity suggests that it will exhibit a favorable safety and tolerability profile compared to racemic MDMA or the S enantiomer. We are currently conducting comprehensive preclinical studies to facilitate sponsored clinical research studies of R-MDMA beginning in 2023. Additionally, through our research collaboration with University Hospital Basel, we plan to initiate a comparative phase I pharmacokinetics and pharmacodynamics study of R, S, and racemic MDMA in mid-2022. Moving on to digital medicine. Our drug development strategy is closely complemented by a platform of digital medicine products that have the potential to facilitate adoption, use, and access to our therapeutics. In February 2021, the company completed the acquisition of HealthMode and fully integrated its team to enable rapid progression of our digital medicine and business operations functions. With that team in place, we engaged in a productive pre-submission meeting with FDA in late 2021. In January of this year, the first subjects were enrolled into the Session Monitoring System SMS-01 study. SMS-01 is evaluating the passive collection of sensory data during a consciousness altering therapeutic session using the MindMed Session Monitoring System or MSMS. MSMS is a technological platform that provides the foundation for the development and implementation of a suite of products for use by clinicians and patients during treatment sessions that may also include the use of consciousness altering medications. The launch of this study is an important milestone for our future development of regulated devices and software as medical devices or SaMD products that are designed to support novel analyses of multimodal data in the delivery of psychiatric care. The study will provide data that support the development of critical analysis algorithms. Subsequent studies will intend to provide the evidence necessary for FDA clearance. The second of our key active digital medicine efforts, called Anxiety Digital Diagnoses for Precision Psychiatry, or ADDAPT, is a combination of a natural history study and a newly developed mobile application to support the study. The study and its supporting app are expected to launch in private beta in the second quarter of 2022. Our third key digital medicine effort progressed such that in September 2021, the first participants were enrolled by invitation in the Quantifying the Processes and Events of Psychotherapy at Scale study, which will provide a rich data set to enable a better understanding of patient progression, trends, and characteristics in the real-world treatment environment and inform all aspects of our program planning. We believe our digital medicine products and projects could have monitoring and therapeutic benefits across a range of psychiatric disorders. By refining the techniques used to capture, model, and map the autonomic and behavioral outflow and other correlates of neural activity, we aim to improve the experience of clinicians and the outcomes for patients in the delivery of psychedelic and other perception-altering substances and psychotherapies. Our team has worked incredibly hard to advance this product into the clinic, and we remain dedicated to rolling out these novel approaches and improving psychiatric outcomes for patients. Overall, we are extremely excited about these advancements and the value-driving milestones ahead. With that, I will turn the call over to Dr. Miri Halpern-Wernli, our Executive President, to discuss our exciting research collaborations and early-stage research and development activities. Thank you, Dan. In addition to our sponsored development programs, over the past year, we have significantly strengthened our early research and development capabilities, both internally and through the external collaborations we have in place with leading academic and research organizations around the world. Before we dive into our ongoing collaborations, I want to highlight the critical role that academic institutions have played in advancing the psychedelic landscape despite the many obstacles and regulatory hurdles. As a company whose mission is to unlock new pathways to improve patient outcomes in brain health disorders, we are proud to join efforts with pioneers in the field to advance the understanding and development of new treatment modalities and biopharmaceuticals. Now to our specific ongoing projects. Let me begin by discussing our collaboration with the Liechti Lab at the University Hospital Basel in Switzerland. Under this partnership, we retained exclusive worldwide rights to data, compounds, and patents associated with their research program evaluating LSD and MDMA, and the collaboration was extended last year to also include 2 additional psychedelic compounds, mescaline and DMT. This includes data from preclinical studies as well as 17 completed and 7 ongoing clinical trials. Our ongoing research collaboration with the UHB Liechti Lab has generated a number of patent applications based on preclinical and clinical data collected over the past decade. The data coming out of this partnership have been invaluable in accelerating our drug development programs. The Liechti Lab recently published a peer-reviewed paper in Neuropsychopharmacology comparing the acute effects of LSD and psilocybin in healthy subjects. The study demonstrated that the key differences between LSD and psilocybin are dose-dependent rather than substance-dependent. This study further expands our knowledge and has the potential to inform future studies evaluating the therapeutic utility of psychedelics. We also have a research collaboration with the Kuypers Lab at Maastricht University in the Netherlands to evaluate the potential benefits of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotional regulation, quality of life, and immune system response. Our academic phase II study in Maastricht University was initiated in Q4 2021 and continues to progress. Additionally, we have an ongoing collaboration partnership with MindShift Compounds AG in Basel, Switzerland, on a drug discovery and optimization platform, developing and characterizing next-generation compounds with psychedelics and/or empathogenic properties with both acute perceptual effects and non-perceptual effects. The partnership on these initial targets is aimed at expanding our own current well-established clinical pipeline. The related intellectual property and pharmaceutical technology will be owned outright by MindMed. Lastly, our ongoing research collaboration with the Israeli innovative drug development company, Nextage Therapeutics, seeks to explore the therapeutic utility of a proprietary brain targeted liposome drug delivery technology to mitigate risk of peripheral adverse effects. Utilizing this technology, we are collaborating with Nextage to develop a proprietary formulation of ibogaine derivatives, seeking to minimize the systemic exposure while maintaining effective concentrations in the brain. The application of liposome to assist drug delivery has already had a major impact on a number of biomedical areas, showing benefits for stabilizing therapeutic compounds and improving biodistribution of compounds to target sites. I will now turn it back over to Rob Barrow. Thank you, Miri. We'll now turn to our financial results for the fourth quarter and fiscal year ended December 31, 2021. As of December 31, 2021, MindMed had cash totaling $133.5 million compared to $80.1 million as of December 31, 2020. MindMed believes its available cash and equivalents will be sufficient to meet its operating requirements beyond its key development milestones and into 2024. The net cash used in operating activities were $45.8 million for the year ended December 31, 2021, compared to $23.6 million for the same period in 2020. R&D expenses were $34.8 million for the year ended December 31, 2021, compared to $18.6 million for the year ended December 31, 2020. The increase was primarily due to an increase of $2.3 million in expenses related to our MM-120 clinical research, $2 million in expenses related to our MM-110 clinical research, $3.5 million in expenses related to other research programs. Internal costs increased $11.1 million, primarily related to an increase in non-cash expenses of $6.6 million of stock-based compensation and $2.6 million in amortization of our developed technology. G&A expenses were $59.1 million for the year ended December 31, 2021, compared with $14.4 million for the year ended December 31, 2020. The increase was primarily due to higher professional services and personnel costs to support the growth of the company and an increase of $28.9 million in non-cash stock-based compensation expenses. Excluding stock-based compensation, G&A expenses were $29.7 million for the year ended December 31, 2021, compared to $13.3 million for the year ended December 31, 2020. The net comprehensive loss was $92.3 million for the year ended December 31, 2021, compared to $33.7 million for the year ended December 31, 2020. Overall, 2021 has been an extraordinary year for MindMed, through which we made huge strides in building a world class pharmaceutical organization that is well positioned to deliver important therapies to patients in need and to deliver significant value to our shareholders. We have been very fortunate to attract top talent within our organization at every level, including with significant additions to our executive management team, board of directors, and scientific advisory board. I'm incredibly proud of our numerous achievements across all areas of the organization, and I cannot be more grateful for the incredible people both within and outside our organization who make this critical work possible. We expect 2022 to be another significant year in the growth of MindMed as we continue advancing our drug and digital medicine pipeline. With that, I'd like to thank you all again for being here today, and I'm happy to take any questions. Ladies and gentlemen, the floor is now open for questions. If you would like to ask a question, please press star one on your telephone keypad at this time. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Once again, that is star one to register a question at this time. Our first question is coming from Patrick Trucchio of H.C. Wainwright. Please go ahead. Thanks. Good morning and congrats on all the progress. First, a couple of questions on MM-120. We have a few follow-up questions around the trial design and expectations around the phase II dose optimization trial in anxiety disorder. Just first, how is the dose of 200 micrograms selected? As well, how many preparation and integration therapy sessions are anticipated? How long are those sessions anticipated to last, and would they be conducted in person or virtually? Then just what is the placebo or control in the trial expected to be? Great. Thanks so much, Patrick. To take your first question, the dose range and the doses were selected in part driven by past research studies on LSD, which have looked at, in particular, a recent study our colleagues out of UHB looked at doses of 25, 50, 100, and 200 micrograms, and characterized the pharmacokinetics and pharmacodynamics of those doses. When we approached this study, looking at those four dose levels plus the placebo control, both allowed us to leverage those preliminary PK/PD data, but also gives us the breadth of exposure across a full dose range we can really optimize and select a key dose to take forward into the pivotal efficacy studies. The statistical methodology we've been using also supports the need to look across a broad spectrum. To have a roughly tenfold difference in exposure from the low dose to the high dose, or when you include the placebo 0 up to 200 micrograms, allows us to maximize our statistical power, but while also leveraging those PK/PD results. Yes, about the placebo. Really, there's been a lot of dialogue, of course, around the appropriate choice of placebo in these clinical trials. Because we're doing a dose optimization study and we have five treatment arms, including the placebo, we felt that a true placebo control was appropriate, as a control condition. That said, the 25-microgram dose also serves as a sub-perceptual sub-experiential dose of LSD, and therefore we view both of those as somewhat of controls. Nonetheless, it is a dose optimization study, and we're looking at the response curves across this dose range. Including the placebo control and looking at each of these dose levels will be inherently important in assessing the response across the full range. It will allow us to choose a dose to move into pivotal studies that we can ultimately select a single comparator against. Yeah. That's helpful. Just, you know, I think it was mentioned that there would be one or it's expected to have the one active session, and so I'm just wondering, I guess how is the protocol kind of determine how does the kind of regulators kind of view the kind of therapy sessions and is there, you know, is there a way that you could have some of those sessions done virtually or how should we think about that? Yeah. I think it's important to contextualize exactly what you're asking, which is the role of psychotherapy. We obviously, when we zoom out and think globally, psychotherapy we view as a critical in the care of patients and essential for maximizing patient outcomes. That said, in the clinical research realm, we explicitly are not delivering psychotherapy as a part of this protocol. There is of course a level of patient education that goes into prior to a dosing session, making sure the patients are ready for the treatment administration. There's a very rigorous level of oversight during the treatment session, which includes observation by two individuals, and this has become standard for all drugs in this class. There are additionally follow-up visits, but none of these are psychotherapeutic in the, by definition, in our protocol and so they wouldn't qualify as psychotherapy as you think about it traditionally. Got it. That's helpful. If I may just one on MM-110. With the phase I trial evaluating MM-110, regarding that top line release, what do you anticipate providing at that time? Would there be any biomarker imaging or other data give further confidence that the compound is demonstrating a more acceptable safety and tolerability profiles compared to ibogaine? Certainly one of the key features that we're gonna be looking at in those clinical results would be the cardiovascular risk. That seems to be the number one liability with ibogaine based on its hERG inhibition and proarrhythmic effects. We did do a characterization of the cardiovascular risk profile and along with the safety and tolerability and PK of MM-110. Overall it's gonna be generally what you would anticipate from a phase I clinical study and all the endpoints are described on clinicaltrials.gov. There are not any biomarkers for clinical efficacy in this study. We certainly are looking at the data to fully characterize safety and tolerability, but also glean whatever we can about, of course, the CNS exposure and the potential to confirm that we're seeing CNS activity. As we look at these results in the context of a typical phase I study, I think it would be really, quite interesting when we see the comparisons to what we know in the literature about ibogaine and also, what we can glean from this in terms of the likelihood of having some CNS effects. Yep. That's very helpful. Thank you so much. Thanks, Patrick. Once again, that is star one if you would like to register a question at this time. Our next question is coming from Sepehr Manochehry of Eight Capital.. Please go ahead. Thanks and congrats on the continued progress. With regards to the program that is enrolling currently, just can you give me some color on the level of enrollment? I think you mentioned there's 52 patients. When do you expect the last patient to be enrolled? I guess, do you have visibility on pre-qualified subjects? Yeah. Thanks. I think you're referring to the ADHD study that's ongoing at the moment with LSD. Yeah. Yeah. Yeah, exactly. That study is ongoing. The December announcement. Just wondering since then how many- Yeah. have been enrolled. Absolutely. Yeah. We haven't made public the current enrollment, and we typically don't, you know, announce ongoing enrollment rates from our studies. We still anticipate a readout in the second half of 2023 from that study. Sorry, that's second half of 2023, correct? Correct. Okay. Just wondering in terms of like, are there levers in place that you guys could play with to whether it's accelerated enrollment or like just looking at the duration of some of these trials. I think that one was the six-week trial. What translates to this kind of late 2023 readout timeline? Is there any levers you can pull to pull that forward? The first thing that comes to my mind would be maybe more sites or qualifying pre-qualifying patients. Yeah. Is there anything you can point me to that might make that a little bit of a conservative estimate or is that what you're thinking? It's definitely our anticipation at this point. We don't have plans to enroll sites beyond those that we've already announced. You know, we have all of the levers available to us. Any of these studies, there are some specific requirements for the patients to enroll in terms of concomitant medication use and the need to wash out. Ultimately, working with Schedule I controlled substances creates additional burden for site startup and the ability to fully enroll, perhaps at the same rate you'd see with a non-controlled substance in certain instances. We are always looking and trying to ensure we get clinical readouts as quickly as possible. We have a number of options available to us, but at this point, we're continuing on the plan we have in place. Understood. With regards to the phase IIb, maybe is there or any of your other trials, do you have particular partnerships in place or sources of data that give you insight into potential pre-qualified patients or patients you could pre-qualify? Or is it going through your third parties that are conducting, basically operating, the trial sites and going through enrollment there? Yeah. Typically, the enrollment for these studies is largely driven and recruitment efforts are largely driven at a site level. We actually have seen elsewhere from some of our peers that casting the net even broader and going for centralized recruitment efforts can, in some instances, muddy the waters further. You can get a huge volume of patients, but actually screening those patients becomes a recruitment challenge in itself to actually get to eligible patients. We do have multiple layers of recruitment activities that we'll be pursuing both at a site level, and that's where we largely rely at the outset. Then as we progress, as we identify enrollment rates, we can always, to use your terminology, pull additional levers to enhance enrollment and patient availability. Central to these studies is really having sites that know their local population, that know their patients, and are able to go out and recruit them. Understood. No, that makes sense. With regards to, I guess, the formulation side of things, are there any hurdles in place for you to initiate the phase IIb in terms of having enough compound or at a certain level of purity that you do require for phase IIb, or you can outside of the U.S. jurisdiction? Like, is there any hurdles there, or are those ready to go? All the requisite information that would be required both on the quality and CMC package and as well as on the clinical and non-clinical side was included in our IND submission. We will certainly be updating that as we progress. Everything was included in our IND submission that was ultimately cleared by FDA. We feel very confident and have the materials available and that we'll be able to progress to that study in Q2. Awesome. Just one question. I know there's the LSD, the trip stopper, the ketanserin. Is that something that you expect an anticipated readout on in the near term? Yeah. Studies such as that, we are continuing the progress of that study. Studies such as that and the investigator-initiated studies that we conduct with our colleagues at University Hospital Basel are subject to their disclosure timelines and largely come out via publication. While we have rights to the data, they're not driven by our corporate readouts as a trial that we sponsor would be. We are anticipating a readout from that study this year, although the precise timing of that is gonna be subject to publication timelines and the re-release criteria at the university. Understood. Maybe some key industry events or conferences, things like that, so we'll look out for those. Absolutely. Awesome. Thank you. Thanks, Sep. Thank you. This concludes the question and answer portion of the call. I will now turn the call back over to MindMed's CEO, Robert Barrow, for closing comments. Mr. Barrow? Great. Thank you, and thank you everyone again for being here this morning. Before we conclude, I'd also like to thank our entire team at MindMed, our investors, our analysts, and the many people who have made this all possible and have been supportive along the way, including, in particular, our study participants and their families. This is a critically important time in the treatment of brain health disorders, and we're very excited to be a part of it. I'd like to thank you all again and look forward to reconnecting in the future. Ladies and gentlemen, thank you for your participation. This concludes today's event. You may disconnect your lines or log off the webcast and enjoy the rest of your day.